The axial phenotype of psoriatic arthritis (axPsA) is an excellent example of a major controversy in rheumatology that has become the focus of attention because of the emergence of new therapies with different mechanisms of action for alleviating joint inflammation. It was first described in 1961 but, until recently, it has largely remained under the…
When Moll and Wright first described the spondyloarthritides in the early 1970s, the archetype of the group was ankylosing spondylitis (AS).1 The shared clinical features of the spondyloarthritides were sacroiliitis; asymmetric large joint peripheral arthritis; psoriasis or psoriaform skin lesions, including keratoderma blennorrhagica; uveitis; and bowel inflammation. Moll and Wright described five clinical subgroups of…
At the 17th Annual Advances in the Diagnosis and Treatment of the Rheumatic Diseases meeting at Johns Hopkins School of Medicine, Baltimore, Atul Deodhar, MD, discussed ankylosing spondylitis and non-radiographic axial spondyloarthritis & clarified common misconceptions about these conditions.
Spondyloarthropathy (SpA) can be difficult to diagnose, with rheumatologists sometimes relying on classification criteria designed for clinical trials. Research examines how the use of MRIs affects the finding of bone marrow edema and the diagnosis of axial SpA.
Spondyloarthropathy is an ancient form of arthritis shared by multiple orders and classes of the animal kingdom. Camarasaurus, a genus of quadrupedal, herbivorous dinosaur, holds the record for the earliest known case of spondyloarthropathy—147 million years ago.
Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options; others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used to…
The differences between axial spondyloarthropathy (axSpA) and axial involvement in psoriatic arthritis (axPsA) have clinical and therapeutic implications. Three experts discussed the distinctions during ACR Convergence 2021.
At the ACR Convergence session CARE: Spondyloarthritis, Alexis Ogdie, MD, presented key principles of diagnosis & management of patients with spondyloarthritis.
Researchers shared findings on the immune response to COVID-19 vaccination in immunocompromised patients, insights into cognitive impairment in SLE & more.
Two experts described the measurements of disease activity used in axial spondyloarthritis and psoriatic arthritis and how rheumatologists can apply them in practice.